Cellceutix Corp. was pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. Conducted by CEOCFO Senior Editor Lynn Fosse, the interview highlighted the distinctiveness of Cellceutix and the reasons why the company stands out from all other biotech companies in the industry.
Mr. Ehrlich discussed the progressions of KM-391, Cellceutix’s compound for the treatment of autism, and Kevetrin, which is being developed as a treatment for drug-resistant cancers. He also explained why their autism drug is revolutionary as there is no drug currently available for the treatment of autism. Additionally, Mr. Ehrlich discussed the company’s growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.
“We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market,” Mr. Ehrlich stated. “Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound.”
“We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy,” commented Mr. Ehrlich.
The full interview can be found at the following link:
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: no positions